Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Oxybutynin Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 13 USDMF, 10 CEP/COS, 3 JDMF, 2 EU WC, 1 KDMF, 11 NDC API, 9 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers, 61 FDA Orange Book, 12 Europe, 10 Canada, 5 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 Evonik, 2 Rochem International Inc, 20 SPI Pharma, 7 DKSH, 7 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Capital Farma, 1 ACG Worldwide, 12 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 30 BASF, 1 Clariant, 14 Corel Pharma Chem, 7 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 12 Gangwal Chemicals, 9 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 29 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 2 Valens Pharmachem, 5 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

85 Fillers, Diluents & Binders, 66 Coating Systems & Additives, 41 Controlled & Modified Release, 35 Direct Compression, 31 Disintegrants & Superdisintegrants, 30 Solubilizers, 28 Granulation, 28 Taste Masking, 27 Film Formers & Plasticizers, 27 Thickeners and Stabilizers, 24 Parenteral, 23 Lubricants & Glidants, 18 Topical, 17 Chewable & Orodispersible Aids, 16 Co-Processed Excipients, 9 Emulsifying Agents, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

17 News #PharmaBuzz

17 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 13 Regulatory FDF Prices

MARKET PLACE

8 APIs

8 APIs

PATENTS & EXCLUSIVITIES

3 US Patents, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/03/2025	PCAS	France	Samoh Pharmaceutical Co., Ltd.	20220113-209-J-1211	Oxybutynin hydrochloride	2022-01-13	PCAS	France	19 route de Meulan, LIMAY, 78520, France

Oxybutynin Hydrochloride

Oxybutynin Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers

13 USDMF

10 CEP/COS

3 JDMF

2 EU WC

1 KDMF

11 NDC API

9 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers

61 FDA Orange Book

12 Europe

10 Canada

5 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

4 Evonik

2 Rochem International Inc

20 SPI Pharma

7 DKSH

7 Faran Shimi Pharmaceutical

1 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 Capital Farma

1 ACG Worldwide

12 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

30 BASF

1 Clariant

14 Corel Pharma Chem

7 DFE Pharma

3 Doshion Polyscience

2 Finar

12 Gangwal Chemicals

9 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

37 Kerry

3 Kima Chemical

6 Lonza Capsugel

16 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

2 Novo Excipients

3 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

29 Roquette

14 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

2 The Dow Chemical Company

2 Valens Pharmachem

5 Vasa Pharmachem

1 Vertellus

1 Zhejiang Huakang Pharmaceutical

TABLET, EXTENDED RELEASE;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GEL;TRANSDERMAL - 10% (100MG/PACKET) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons